SOLJULI

Serial Number 98007303
731

Registration Progress

Application Filed
May 22, 2023
Under Examination
May 14, 2024
Approved for Publication
Feb 28, 2024
Published for Opposition
Mar 19, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 2 Granted
Due: Nov 14, 2025 124 days

Trademark Image

SOLJULI

Basic Information

Serial Number
98007303
Filing Date
May 22, 2023
Published for Opposition
March 19, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
731
Status Date
Mar 27, 2025
Application
Pending
Classes
005

Rights Holder

Lupin Limited

16
Address
Bandra Kurla Complex; Bandra (W) B/4
Laxmi Towers
Mumbai 400051
IN

Ownership History

Lupin Limited

Original Applicant
16
Mumbai IN

Lupin Limited

Owner at Publication
16
Mumbai IN

Legal Representation

Attorney
Robert L. Powley

USPTO Deadlines

Next Deadline
124 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
November 14, 2025
Extension Available
Until May 14, 2025

Application History

17 events
Date Code Type Description
Mar 28, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 27, 2025 EX2G S SOU EXTENSION 2 GRANTED
Mar 27, 2025 EXT2 S SOU EXTENSION 2 FILED
Mar 27, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 21, 2024 EXT1 S SOU EXTENSION 1 FILED
Jun 21, 2024 EX1G S SOU EXTENSION 1 GRANTED
Jun 21, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 21, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
May 14, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 19, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 19, 2024 PUBO A PUBLISHED FOR OPPOSITION
Feb 28, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 28, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 15, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 14, 2024 DOCK D ASSIGNED TO EXAMINER
Jun 23, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 25, 2023 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
pharmaceuticals, namely, contraceptives; oral contraceptives; oral hormonal contraceptives; contraceptive preparations and substances; hormone replacement therapies; hormonal agents for treating disorders and conditions related to women's health, namely, symptoms and conditions associated with menopause, pre-menstruation syndrome and other symptoms and conditions associated with menstruation

Classification

International Classes
005

USPTO Documents

Loading USPTO documents...